Literature DB >> 26488700

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Nicholas C Turner, Cynthia Huang Bartlett, Massimo Cristofanilli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26488700     DOI： 10.1056/NEJMc1510345

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  41 in total

Review 1.  Precision medicine for advanced prostate cancer.

Authors:  Stephanie A Mullane; Eliezer M Van Allen
Journal:  Curr Opin Urol       Date:  2016-05       Impact factor: 2.309

Review 2.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Authors:  Erik S Knudsen; Steven C Pruitt; Pamela A Hershberger; Agnieszka K Witkiewicz; David W Goodrich
Journal:  Trends Cancer       Date:  2019-04-30

3.  Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG.

Authors:  Francisco J Cordero; Zhiqing Huang; Carole Grenier; Xingyao He; Guo Hu; Roger E McLendon; Susan K Murphy; Rintaro Hashizume; Oren J Becher
Journal:  Mol Cancer Res       Date:  2017-05-18       Impact factor: 5.852

Review 4.  Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.

Authors:  Dumessa Edessa; Mekonnen Sisay
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-12-06

5.  PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.

Authors:  Doudou Huang; Lin Tang; Fang Yang; Juan Jin; Xiaoxiang Guan
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

6.  Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Authors:  Valerie M Jansen; Neil E Bhola; Joshua A Bauer; Luigi Formisano; Kyung-Min Lee; Katherine E Hutchinson; Agnieszka K Witkiewicz; Preston D Moore; Mónica Valéria Estrada; Violeta Sánchez; Paula G Ericsson; Melinda E Sanders; Paula R Pohlmann; Michael J Pishvaian; David A Riddle; Teresa C Dugger; Wenyi Wei; Erik S Knudsen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

7.  In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.

Authors:  Michiko Kodama; Takahiro Kodama; Justin Y Newberg; Hiroyuki Katayama; Makoto Kobayashi; Samir M Hanash; Kosuke Yoshihara; Zhubo Wei; Jean C Tien; Roberto Rangel; Kae Hashimoto; Seiji Mabuchi; Kenjiro Sawada; Tadashi Kimura; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-15       Impact factor: 11.205

Review 8.  Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy.

Authors:  Diyang Xie; Zhenggang Ren; Jia Fan; Qiang Gao
Journal:  Am J Cancer Res       Date:  2016-02-15       Impact factor: 6.166

9.  ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Authors:  Hetal Patel; Manikandan Periyasamy; Georgina P Sava; Alexander Bondke; Brian W Slafer; Sebastian H B Kroll; Marion Barbazanges; Richard Starkey; Silvia Ottaviani; Alison Harrod; Eric O Aboagye; Laki Buluwela; Matthew J Fuchter; Anthony G M Barrett; R Charles Coombes; Simak Ali
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

Review 10.  Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents.

Authors:  Catherine Terret; Chiara Russo
Journal:  Drugs Aging       Date:  2018-02       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.